期刊文献+

CHOP与CHOPE方案治疗非何杰金淋巴瘤的临床观察

下载PDF
导出
摘要 目的比较CHOP(环磷酰胺、阿霉素、长春新硷和强的松)与CHOPE(环磷酰胺、阿霉素、长春新硷、强的松和足叶乙甙)方案治疗低、中危侵袭性淋巴瘤的疗效及毒副作用。方法43例患者随机分为两组,CHOP21例。环磷酰胺(CTX)750mg/m2,静脉注射,第1天。长春新硷(VCR)1.4mg/m2,静脉注射,第1天,第8天。阿霉素(ADM)40mg/m2,静脉注射,第1天。强的松100mg/d,连服5天。每21天为1个周期。CHOPE22例,CHOP的基础上加用足叶乙甙(VP-16)100mg/d,静脉点滴,第1~5天。至少治疗3周期评价疗效。结果CHOPE方案对于年龄<60岁低、中危患者在完全缓解率及有效率明显高于CHOP方案,毒副作用两组相似,主要表现在骨髓抑制、消化道反应及末梢神经炎。结论对于低、中危侵袭性淋巴瘤的患者一线治疗可以考虑用CHOPE方案。
出处 《齐齐哈尔医学院学报》 2007年第13期1556-1557,共2页 Journal of Qiqihar Medical University
  • 相关文献

参考文献4

  • 1Inoue R,Natazuka T,Shimoyama M,et al.Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's.aggressire Lymphoma:a pilot study[J].Leck Lymphoma,2000,36(3-4):315-321
  • 2韩锐.肿瘤化疗的临床药理学[M].天津:天津科学技术出版社,1996:661-711
  • 3路平,冷传春,梅家转.DICE作为二线方案治疗难治或复发性非霍奇金淋巴瘤[J].中国肿瘤临床,2003,30(5):313-315. 被引量:16
  • 4Michael P,Lorenz T,Marita K,et al.2-weekly or 3-weekly CHOP chemotherapy with or without Etoposide for the treatment of young patients with good-prognosis(normal LDH)aggressive lymphomas:Results of the NHL-B1 trial of the DSHNHL[J].Blood,2004,104(3):626-633

二级参考文献11

  • 1[1]Fisher RI, Gaynor ER, Dahlberg S, et al. Comparion of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J]. N Engi J Med, 1993,328:1002
  • 2[2]Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized inter-mediate and high-grade non-Hodygkin's lymphoma[J]. N Engl J Med, 1998,339:21
  • 3[3]Schenkein DP, Roitman D, Miller KB, et al. A phase Ⅱ multicenter trial of high dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high risk non-Hodygkin's lymphoma [J]. Biol Blood Marrow Transplant, 1997,3(1):210
  • 4[4]Vose JM. High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse largecell non-Hodgkin' s lymphoma[J]. Ann Oncol, 1998,9(1):1~3
  • 5[5]Gryn J, Johnson E, Goldman N, et al. The treatment of relapsed or refractory intermediate grade non-Hodgkin' s lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon [J]. Bone Marrow Transplant,1997,19(1):221~226
  • 6[6]Buzzoni R, Colleoni M, Nelli P, et al. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma[J].Leuk Lymphoma, Leuk Lymphoma, 1994,14(1):121-128
  • 7[7]Hagemeister FB, Donato M. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience[J]. Eur J Haematol Suppl, 2001,64(1):8~13
  • 8[8]Itoh K, Igarashi T, Ohtsu T, et al. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or re fractory aggressive non-Hodgkin' s lymphoma[J]. Int J Hematol,1998,68 (2):431 ~437
  • 9[9]Garay G, Dupont J, Dragosky M, et al. Combination salvage chemotherapy with MIZE (ifosfamide- mesna, idarubicin and etoposide) for relapsing or refractory lymphoma[J]. Leuk Lym phoma, 1997,26(2):595 ~602
  • 10[10]Haim N, Ben-Shahar M, Faraggi D, et al. Dexamethasone,etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma[J]. Cancer,1997,80(10):1989~1996

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部